Atara Biotherapeutics, Inc. (ATRA)
$
4.45
-0.14 (-3.15%)
Key metrics
Financial statements
Free cash flow per share
-5.1463
Market cap
32.1 Million
Price to sales ratio
0.2112
Debt to equity
-1.5997
Current ratio
1.0208
Income quality
-2.9791
Average inventory
0
ROE
-0.4178
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Atara Biotherapeutics, Inc. is an innovative company focused on off-the-shelf T-cell immunotherapy, dedicated to developing treatments for patients suffering from cancer, autoimmune disorders, and viral diseases in the United States. Currently, it is advancing tabelecleucel, a T-cell immunotherapy undergoing Phase 3 clinical trials to treat Epstein-Barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors like nasopharyngeal carcinoma. Additionally, Atara is working on next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 targeting mesothelin, along with ATA2431 and ATA3219 focused on B-cell malignancies, in addition to ATA188 for multiple sclerosis. The company is also developing the ATA368 program for patients with cancers associated with human papillomavirus. Atara Biotherapeutics has established a license agreement with Memorial Sloan Kettering Cancer Center, alongside a research and development collaboration with QIMR Berghofer Medical Research Institute, as well as strategic partnerships with H. Lee Moffitt Cancer Center and Bayer AG for the development of mesothelin-targeted CAR T-cell therapies designed for solid tumors. Incorporation in 2012 marked the beginning of the company, which is now headquartered in South San Francisco, California. The gross profit stands at $107,931,000.00 highlighting the company's profitability from core operations. The company's stock is identified with the symbol '$ATRA' in the market. The income before tax ratio is -$0.66 reflecting the pre-tax margin. The company reported an income before tax of -$85,415,000.00 showcasing its pre-tax profitability. The financial data pertains to the fiscal year $2024. Atara Biotherapeutics, Inc. is classified as a small-cap player with a market capitalization of $32,085,546.00. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation within the Healthcare sector. The stock is affordable at $12.05 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 295,081.00 indicating lower market activity. This dynamic presence in the market reflects the company's commitment to advancing therapeutic solutions and enhancing patient care.
Is Atara Biotherapeutics, Inc. (ATRA) a good investment?
Investing in Atara Biotherapeutics, Inc. (ATRA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Atara Biotherapeutics, Inc. (ATRA)'s stock forecast?
Analysts predict Atara Biotherapeutics, Inc. stock to fluctuate between $4.20 (low) and $19.15 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Atara Biotherapeutics, Inc.'s market capitalization?
As of 2026-02-13, Atara Biotherapeutics, Inc.'s market cap is $32,085,546, based on 7,210,235 outstanding shares.
How does Atara Biotherapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Atara Biotherapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Atara Biotherapeutics, Inc. (ATRA) stock?
To buy Atara Biotherapeutics, Inc. (ATRA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATRA. Place an order (Market, Limit, etc.).
What is the best time to invest in Atara Biotherapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Atara Biotherapeutics, Inc. stock ever split?
Atara Biotherapeutics, Inc.'s last stock split was 1:25 on 2024-06-20.
How did Atara Biotherapeutics, Inc. perform in the last earnings report?
Revenue: $128,940,000 | EPS: -$11.41 | Growth: -82.49%.
Where can I find Atara Biotherapeutics, Inc.'s investor relations reports?
Visit https://www.atarabio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Atara Biotherapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Atara Biotherapeutics, Inc. stock?
All-time high: $501 (2021-11-04) | All-time low: $4.20 (2026-01-21).
What are the key trends affecting Atara Biotherapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
globenewswire.com
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
globenewswire.com
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
zacks.com
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
Atara Biotherapeutics (ATRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
businesswire.com
THOUSAND OAKS, Calif--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Greg Ciongoli will assume the role of Chair of the Board of Directors. Greg Ciongoli is the founder and managing partner of Adiumentum Capital Management. He has served as a Director at Atara since 2024.
businesswire.com
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The o.
businesswire.com
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2025 and business updates. “We are pleased that we have secured additional financing that is expected to extend our cash runway through the first quarter of 2026,” sai.
businesswire.com
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Atara's active Investigational New Drug (IND) applications for the EBVALLO™ (tabelecleucel) program. “We are very pleased to.
See all news
